Patent intelligence · US
US 8324171
Ophthalmic compositions containing diglycine
Ophthalmic compositions containing diglycine
Patent details — US 8324171
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 4, 2012
- Expiration
- Nov 29, 2032
- Applicant
- BURKE SUSAN E [US]
- CPC classes
- A61K 31/ 14 A I, A61K 38/ 00 A I, A61K/31155, A61K/4718
Quick answer
US 8324171 (Ophthalmic compositions containing diglycine) is held by BURKE SUSAN E [US]. Status: granted. Granted Dec 4, 2012. Expires Nov 29, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BURKE SUSAN E [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 14 A I, A61K 38/ 00 A I, A61K/31155, A61K/4718, A61K/47183, A61K/4720
More from BURKE SUSAN E [US]
Related pharmaceutical patents in our USPTO index.
-
US 2020339710
GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF
granted -
US 2020239601
CROSSLINKED POLYMERIC NETWORK AND USE THEREOF
granted -
US 2019151500
OPHTHALMIC VISCOELASTIC COMPOSITIONS
granted -
CA 3043000
DERIVES DE PROSTAGLANDINE LIBERANT DE L'OXYDE NITRIQUE POUR LE TRAITEMENT DU GLAUCOME A TENSION NORMALE
granted -
US 2016213609
OPHTHALMIC SUSPENSION COMPOSITION
granted -
US 2015038439
METHOD FOR PREPARING SUSPENSIONS OF LOW-SOLUBILITY MATERIALS
granted -
US 2014206764
Poly(Nitrogen/Amine) Derivatives of a Natural Wax and Ophthalmic Compositions
granted -
US 2014142182
Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid
granted
Frequently asked questions
What is US patent 8324171?
US 8324171 (Ophthalmic compositions containing diglycine) is held by BURKE SUSAN E [US]. Status: granted. Granted Dec 4, 2012. Expires Nov 29, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8324171?
BURKE SUSAN E [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 8324171 expire?
Our index shows an expiration date of Nov 29, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.